Precision medicine study for inflammatory bowel disease
Part of Digestive system clinical trials.
This study looks at using precision medicine to treat inflammatory bowel disease (IBD) in people who are newly diagnosed or already being monitored. It aims to find better ways to manage the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 10 years old or older.
- You must have been recently diagnosed with inflammatory bowel disease (IBD) or be under regular follow-up care.
- You must not have been diagnosed with cancer or have a history of cancer treatment.
- Your participation must be approved by the medical team.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood, stool, tissue, and health information from people with inflammatory bowel disease (IBD), their relatives, and healthy volunteers to find patterns that may help diagnose or treat IBD better in the future.
This study follows people who have a parent, sibling, or child with Crohn's disease or ulcerative colitis to help understand why some family members develop the condition. If you are 14 or older and do not already have IBD, you may be able to join.
This trial looks at early signs of inflammatory bowel disease (IBD) in adults who have had stomach or bowel symptoms for at least 3 weeks. It aims to understand how the disease progresses.
This trial tests a personalized approach to starting anti-TNF therapy—a common treatment for inflammatory bowel disease (IBD)—in patients who have never taken it before. The goal is to help doctors choose the right anti-TNF medication and dose based on each patient's individual characteristics.
This study follows patients with inflammatory bowel disease (Crohn's or ulcerative colitis) to better understand abnormal growths in the colon (dysplasia) and their risk of turning into cancer. It aims to improve how we predict and prevent cancer in IBD patients.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.